The report provides a detailed analysis essential for establishing a betrixaban production plant. It encompasses all critical aspects necessary for betrixaban production, including the cost of betrixaban production, betrixaban plant cost, betrixaban production costs, and the overall betrixaban production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a betrixaban production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Betrixaban is a synthetic anticoagulant drug that is mainly used to prevent blood clots in certain hospitalised patients. It is widely used as a medication to prevent blood clots in patients who are at risk of developing venous thromboembolism (VTE), especially during long hospital stays. It works by blocking Factor Xa, which is an important protein involved in the blood clotting process, thereby reducing the chances of clot formation. It also finds its application in preventing deep vein thrombosis (DVT) and pulmonary embolism in patients hospitalised with an acute medical condition who are at high risk for venous thromboses. It is often prescribed for extended use after discharge to continue protection in high-risk patients. Moreover, it is valued for its once-daily dosing and reduced need for frequent monitoring compared to some traditional anticoagulants. It is also used as a reference compound in ongoing research studies to develop treatment for other cardiovascular and thrombotic disorders.
The primary factor that drives the market for betrixaban is its demand as an oral anticoagulant used to decrease the risk of deep vein thrombosis and pulmonary embolus in hospitalised patients. Its application in the management of deep vein thrombosis or pulmonary embolism (PE) in patients with limited mobility due to illness or surgery further drives its demand in the medical sector. Its usage as a medication in managing clot-related complications in certain high-risk medical conditions, where prolonged clot prevention is needed, further supports its demand in the medical and pharmaceutical industries.
Moreover, its role in reducing the risk of deep vein thrombosis and pulmonary embolism, especially in high-risk medical patients, further increases its adoption across hospitals and speciality clinics. Furthermore, advancements in drug formulation, dependable supplier partnerships, and efficient distribution networks significantly impact industrial betrixaban procurement globally. Factors such as the cost and availability of active pharmaceutical ingredients and intermediates, strict regulatory approvals, and quality standards for anticoagulant drugs also shape its procurement strategies.
Raw Material for Betrixaban Production
According to the betrixaban production plant project report, the major raw materials for betrixaban production include 4-(N,N-dimethylcarbamimidoyl)benzoic acid and 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide.
Production Process of Betrixaban
The extensive betrixaban production cost report consists of the following industrial production process:
- Production via Condensation: The production process of betrixaban begins with the condensation of 4-(N,N-dimethylcarbamimidoyl)benzoic acid and 2-amino-N-(5-chloropyridin-2-yl)-5-methoxybenzamide. The reaction involves forming an amide bond between the carboxylic acid group of the benzoic acid derivative and the amino group of the benzamide component. This main step results in the formation of a secondary carboxamide linkage, which produces betrixaban as the final compound after purification.
Betrixaban is a synthetic anticoagulant that acts as a highly potent, selective, and reversible direct inhibitor of coagulation factor Xa. It appears as an off-white solid powder that is slightly soluble in DMSO and methanol. The molecular formula of the compound is C23H22ClN5O3, and its molar mass is 451.91 g/mol. It has a density of approximately 1.30 g/cm³, and the compound has a melting point of 210–213 degrees Celsius. It is generally marketed under the brand name Bevyxxa. The compound should be stored at 2–8 degrees Celsius to maintain its stability. It is classified as a hazardous substance, and it is harmful if swallowed. Prolonged or repeated exposure to this compound may cause damage to organs, particularly affecting the blood. It is recommended to wear protective clothing and gloves while handling the compound, and in case of ingestion, immediate medical attention should be sought.